NCT04647357

A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer

A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer Without Progression After First Line Concurrent Chemoradiotherapy Treatment

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

SHR-1316 as Maintenance therapy for limited stage small cell lung cancer without progression after first line platinum based concurrent chemoradiotherapy

Conditions

• Limited-stage Small Cell Lung Cancer, LS-SCLC

Interventions

Type	Name	Description
DRUG	SHR-1316	Anti-PD-L1 antibody，Maintenance therapy, The drug was administered every three weeks

Timeline

• Start date: 2020-11-27
• Primary completion: 2023-05-27
• Completion: 2023-12-27
• First posted: 2020-11-30
• Last updated: 2020-11-30